TMS also detects some untreatable diseases and can miss some treatable disorders in each category, thus one should set up the instrument and computer program to flag only the diseases selected in individual screening program.
In addition to TMS, it is also desirable to add 3 more techniques for a complete screening program: 1) Gas chromatography and mass spectrometer for urine organic acid analysis to confirm diagnosis of organic acidemia and certain fatty acid oxidation disorders; 2) An amino acid High Performance Liquid Chromatography (HPLC) to confirm diagnosis of aminoacidopathies; and 3) AutoDELFIA system for the diagnosis of disease that cannot be identified by TMS namely congenital hypothyroidism, biotinidase deficiency, galactosemia, congenital adrenal hyperplasia, cystic fibrosis, etc.
Selection of diseases in the screening panel should be based on the priorities of the individual country. In this regard, the Wilson and Jungner criteria can serve as a useful guide. 6 Basically, consideration should be given to disease prevalence and the cost vs. benefit of screening and treatment. From the experience of running metabolic disease services in Oman, 7 a program is proposed incorporating common diseases that can be treated by simple and cost effective means. After a period of 3 to 5 years' experience, more diseases can be added gradually to reach an expanded program. Some other diseases that can be diagnosed by simple tests prior to discharge of a baby from the hospital are also important to include in the Expanded Screening Program: 1) Screening for congenital deafness by Oto-accoustic Emission testing, 8 2) Screening for cyanotic congenital heart diseases by pulse oxymetry, 9 and 3) Bilirubin check to predict risk for hyperbilirubinemia using Bhutani' s nomogram. 10 It is also important to decide the timing to perform the screening test. The best time is after 48 hours of normal feeding so that enough metabolites are accumulated for detection and to avoid TSH surge following the birth stress. At the present time, there is a tendency to discharge mother and baby within 24 hours of normal delivery; in such cases, the test must be done just prior to discharge after the baby has consumed at least 3 normal feeds.
Oman has a good healthcare network of 57 hospitals and 136 health centers. The National Congenital Hypothyroidism screening has been in operation since 2004. Tandem MS has been in operation at the Sultan Qaboos University Hospital for metabolic diagnostic services since 2002 giving the institution a wealth of clinical and technical expertise.
11 It is therefore, quite possible that this screening program can be easily broadened to successfully accommodate the proposed screening program.
Main barriers to screening program in Oman are cost, availability of diagnostic and treatment facilities, public and healthcare worker education, difficulties in reaching many geographical locations, and recalling positive cases. With the recent establishment of a Genetic Centre at MoH and availability of services of three new geneticmetabolic specialists, such a task would not be difficult. However, the full commitment of the Ministry of Health to bear the cost of screening and disease management is necessary.
Like other Gulf countries, Oman has 52% consanguinity and metabolic diseases are at least 3 to 5 times more common. Birth rate in the country is about 45,000 per annum, which will require at least 123 screening tests per day. This will require a medium sizescreening laboratory.
In the Gulf region, 12 Qatar has already been running a full newborn screening program since 2004 in collaboration with the University Children Hospital of Heidelberg, Germany. Until recently, Saudi Arabia had a program covering only 25% of all newborns through selected hospitals; however, the Ministry of Health has recently given the permission to launch a nationwide screening program. UAE has also expanded its screening program in 2010. It can therefore be categorically said that the time for newborn screening for Oman is here and now. The investment in screening will certainly be rewarded many times over in terms of money spent over the care of handicapped children, improved quality of life, and reducing the high burden of genetic disease.
